Validating five questions of antiretroviral nonadherence in a public-sector treatment program in rural South Africa.
Simple questions are the most commonly used measures of antiretroviral treatment (ART) adherence in sub-Saharan Africa (SSA), but rarely validated. We administered five adherence questions in a public-sector primary care clinic in rural South Africa: 7-day recall of missed doses, 7-day recall of late doses, a six-level Likert item, a 30-day visual analogue scale of the proportion of doses missed, and recall of the time when an ART dose was last missed. We estimated question sensitivity and specificity in detecting immunologic (or virologic) failure assessed within 45 days of the adherence question date. Of 165 individuals, 7% had immunologic failure; 137 individuals had viral loads with 9% failure detected. The Likert item performed best for immunologic failure with sensitivity/specificity of 100%/5% (when defining nonadherence as self-reported adherence less than "excellent"), 42%/55% (less than "very good"), and 25%/95% (less than "good"). The remaining questions had sensitivities ≤17%, even when the least strict cutoffs defined nonadherence. When we stratified the analysis by gender, age, or education, question performance was not substantially better in any of the subsamples in comparison to the total sample. Five commonly used adherence questions performed poorly in identifying patients with treatment failure in a public-sector ART program in SSA. Valid adherence measurement instruments are urgently required to identify patients needing treatment support and those most at risk of treatment failure. Available estimates of ART adherence in SSA are mostly based on studies using adherence questions. It is thus unlikely that our understanding of ART adherence in the region is correct.
Department of Global Health and Population, Harvard School of Public Health, Boston, Massachusetts, USA.
Krisda
K
Chaiyachati
Lisa R
LR
Hirschhorn
Frank
F
Tanser
Marie-Louise
ML
Newell
Till
T
Bärnighausen
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D008297:Male; D010349:Patient Compliance / Q000523:psychology*; D011634:Public Health; D015203:Reproducibility of Results; D012424:Rural Population; D013019:South Africa / Q000453:epidemiology
D019380:Anti-HIV Agents
Clin Infect Dis. 2001 Sep 1;33(5):700-5
11486292
AIDS Care. 2003 Aug;15(4):463-74
14509861
Nutr J. 2005 May 31;4:19
15927053
J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):26-35
11064501
J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1100-2
15247564
J Acquir Immune Defic Syndr. 2006 Dec 1;43 Suppl 1:S149-55
17133199
AIDS. 2002 Sep 6;16(13):1835-7
12218400
Clin Infect Dis. 2004 May 1;38(9):1311-6
15127346
J Acquir Immune Defic Syndr. 2007 May 1;45(1):4-8
17460469
Infect Genet Evol. 2007 Mar;7(2):333-42
17045554
Braz J Infect Dis. 2003 Feb;7(1):16-22
12807688
AIDS Patient Care STDS. 2008 Sep;22(9):735-43
18754705
Ann Intern Med. 2010 Jan 5;152(1):18-25
20048268
AIDS. 2005 Jan 3;19(1):1-14
15627028
AIDS. 2000 Mar 10;14(4):357-66
10770537
J Infect Dis. 2007 Aug 15;196 Suppl 1:S35-45
17726832
Clin Infect Dis. 2006 Oct 1;43(7):939-41
16941380
Curr HIV/AIDS Rep. 2007 May;4(2):65-72
17547827
J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):435-42
11391162
Arch Intern Med. 2001 Sep 10;161(16):1962-8
11525698
J Antimicrob Chemother. 2008 Feb;61(2):389-93
18096560
JAMA. 2008 Aug 6;300(5):530-9
18677025
Ann Intern Med. 2001 May 15;134(10):968-77
11352698
Gastroenterology. 2009 May;136(6):1965-78
19462506
AIDS Behav. 2008 Jan;12(1):86-94
17577653
PLoS One. 2008 Jul 30;3(7):e2783
18665246
J Acquir Immune Defic Syndr. 2000 Apr 15;23(5):386-95
10866231
J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):445-8
15764962
AIDS Behav. 2007 Jan;11(1):79-86
17028992
AIDS Patient Care STDS. 2010 Mar;24(3):189-95
20214487
AIDS Clin Care. 1998 Aug;10(8):57-9
11365682
Clin Infect Dis. 2001 Oct 15;33(8):1417-23
11550118
AIDS Patient Care STDS. 2006 Oct;20(10):701-11
17052140
AIDS. 2007 May 11;21(8):965-71
17457090
J Infect Dis. 2008 May 15;197 Suppl 3:S272-8
18447613
AIDS Behav. 2006 May;10(3):227-45
16783535
Antivir Ther. 2008;13(5):625-39
18771046
AIDS. 1999 Jun 18;13(9):1099-107
10397541
PLoS Med. 2008 May 20;5(5):e109
18494555
J Acquir Immune Defic Syndr. 2002 Jul 1;30(3):324-34
12131570
J Acquir Immune Defic Syndr. 2008 Jun 1;48(2):216-9
18520681
Bull World Health Organ. 2010 Aug 1;88(8):593-600
20680124
Ann Intern Med. 2000 Jul 4;133(1):21-30
10877736
Clin Infect Dis. 2002 Apr 15;34(8):1115-21
11915001
Int J Epidemiol. 2011 Apr;40(2):318-26
20154009
Antivir Ther. 2007;12(1):83-8
17503751
J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):238-44
17693890
AIDS Res Ther. 2009 Oct 12;6:21
19821997
Trop Med Int Health. 2009 Oct;14(10):1226-32
19732408
Antivir Ther. 2009;14(7):975-84
19918101
JAMA. 2006 Aug 9;296(6):679-90
16896111